The latest announcement is out from Pacific Biosciences (PACB).
In a decisive annual meeting, Pacific Biosciences’ stockholders cast their votes on key proposals shaping the company’s future. Shareholders overwhelmingly approved the election of four director nominees, the ratification of Ernst & Young LLP as the independent auditor, and endorsed the compensation of executive officers. Additionally, they supported the expansion of the 2020 Equity Incentive Plan, voted in favor of declassifying the board over three years, and passed an amendment to limit officer liability in accordance with Delaware law. The meeting showcased strong shareholder engagement with a 75% turnout, reinforcing the company’s strategic direction and governance.
Learn more about PACB stock on TipRanks’ Stock Analysis page.
